ORPHA:424019
Squamous cell carcinoma of the anal canal
Publications
818
82.9th percentile
Trials
11
Interventional, condition-specific
Researchers
1,505
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Squamous cell carcinoma of the anal canal is a rare epithelial intestinal neoplasm, arising from squamous epithelial cells in the anal canal, with variable macroscopic appearance, ranging from small, benign lesions (that mimick fissures, hemorrhoids or anorectal fistulae) to a large, exophytic or ulcerating tumor localized within the anal canal. Patients may be asymptomatic or present difficulty to defecate, anal bleeding, pain and/or discharge, and often have a history of chronic anal fistulae and abscesses, Crohn's disease, hemorrhoids, or, especially in younger patients, immunosuppression (such as HIV infection). Association with HPV infection is commonly reported.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0004132
- UMLS:C1332262
- NCIT:C7469
Additional Mondo synonyms (2)
anal canal squamous cell carcinoma · squamous cell carcinoma of the anal canal
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
818 matched papers (481 in last 10 years) Source
- Phenotype characterisedPresent
12 HPO annotations (e.g. Anal canal squamous cell carcinoma; Neoplasm of the rectum; Neoplasm of the liver) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
11 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
12
Associated phenotypes · MONDO:0004132
- Anal canal squamous cell carcinoma
- Neoplasm of the rectum
- Neoplasm of the liver
- Neoplasm of the skeletal system
- Neoplasm of the lung
Showing 5 of 12 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
818
818 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
818 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
481 in the last 10 years · high confidence · 82.9th percentile (publications denominator)
Phrase hits: 818 · MeSH hits: 0
Who's working on it?
1,505
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Eng C13 papers · 2026
a Department of Gastrointestinal Medical Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Papers in Europe PMC - 02Morris VK9 papers · 2026
Department of Gastrointestinal Medical Oncology, The University of Texas - MD Anderson Cancer Center, Houston, TX, USA.
Papers in Europe PMC - 03Yamada K9 papers · 2026
Department of Surgery, Coloproctology Center Takano Hospital, Kumamoto, Japan.
Papers in Europe PMC - 04
- 05Ajioka Y7 papers · 2025
Division of Molecular and Diagnostic Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Papers in Europe PMC - 06Riechelmann RP6 papers · 2026
Clinical Oncology Department, AC Camargo Cancer Center, Sao Paulo, BR.
Papers in Europe PMC - 07Das P5 papers · 2025
Department of Radiation Oncology, The University of Texas - MD Anderson Cancer Center, Houston, TX, USA.
Papers in Europe PMC - 08Hallemeier CL5 papers · 2025
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, United States.
Papers in Europe PMC - 09Saiki Y5 papers · 2026
Department of Surgery, Coloproctology Center Takano Hospital, Kumamoto, Japan.
Papers in Europe PMC - 10Burandt E4 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
11
interventional trials for this specific condition
11 interventional trials matched this specific condition name; 2 currently recruiting in our sample.
Data as of 11 September 2026
11 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 92.8th percentile).
high confidence · 92.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
11 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05661188·RECRUITING·Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)
Not reviewed·Conditions: Squamous Cell Carcinoma of the Anal Canal·Matched via name phrase
- NCT04429542·RECRUITING·Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Squamous Cell Carcinoma of Anal Canal · Colorectal Cancer · Squamous Cell Carcinoma of the Lung·Matched via name phrase
Observational and natural-history studies
4 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07455942·NOT YET RECRUITING·Towards an Understanding of Barriers and Delays in the Diagnosis of Anal Cancer
Not reviewed·Conditions: Squamous Cell Carcinoma of the Anal Canal · HPV-induced Cancer·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 5 · after dedupe 5 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 5 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (5)
- ctis·2023-509485-38-00·Expired·Phase II study of Atezolizumab plus Tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal.
skipped — LLM skipped (--skip-llm)
- ctis·2024-512331-72-00·Cancelled·INCMGA 0012-303: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN88455282·No longer recruiting·PLATO - Personalising anal cancer radiotherapy dose
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14732216·No longer recruiting·Clinical trial of qHPV vaccine in HIV positive Men who have sex with men
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26715889·No longer recruiting·A second UK Phase III anal cancer trial: a trial of chemoradiation and maintenance therapy for patients with anal cancer
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Squamous cell carcinoma of the anal canal — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Squamous cell carcinoma of the anal canal" OR "Squamous cell carcinoma of anal canal" OR "anal canal squamous cell carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Squamous cell carcinoma of the anal canal" OR "Squamous cell carcinoma of anal canal" OR "anal canal squamous cell carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 11 interventional · 4 observational · 1 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T15:55:10.623Z
